RE:RE:Trial delay is obviously weighing heavily on SP How about some Nova scotia DD.
May 19 Government of Canada says Dalhousie to Trial a Covid 19 Vaccine
[url=https://www.dal.ca/news/2020/05/19/researchers-at-dalhousie-to-lead-human-trials-of-covid-19-vaccin.html[/url]
May 19th the Covid levels were so flat that the government is trialing a Covid 19 vaccine.. I mean come on man Nova Scotia data
The first Canadian clinical trials for a potential COVID-19 vaccine will be led by researchers at Dalhousie University, with testing set to begin as early as the next few weeks. Theralase Advances its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia Toronto, Ontario – February 25, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced that Nova Scotia Health Authority (“NSHA”) Research Ethics Board (“REB”) has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (“CIS”) and who are considered Bacillus Calmette Guerin(“BCG”)-Unresponsive or are intolerant to BCG Therapy (“Study II”). The Nova Scotia provincial cancer rates are among the highest in Canada. It is estimated for 2019 in Nova Scotia that 6,700 people were diagnosed with cancer, and 2,900 people died of cancer1 with bladder cancer cases counting for approximately 5% of cancer diagnosis.2 The NSHA institution is affiliated with the Urology Department at Dalhousie (“UDD”) University of Medicine, an innovative leader in urological oncology research. UDD evaluates new technologies designed to improve the lives of people suffering from urological cancers. Each year, more than 300 people are diagnosed with bladder cancer and seek attention in Nova Scotia.2 UDD doctors have extensive experience providing quality of care for bladder cancer patients while maintaining an active research role to enhance overall patient care. Dr. Ricardo Rendon, MD, FRCSC, Professor in the Department of Urology and Director of Clinical Trial of Dalhousie University in Halifax stated that “We are excited to work with Theralase for the NMIBC clinical trial. Tackling cancer is a crucial topic and a priority for this region, and I am pleased that NSHA is able to contribute to the growth of innovative cancer research by taking part in this leading Pivotal PhotoDynamic Therapy (“PDT”) study.” With the addition of NSHA, the Company now has four sites open for patient enrollment and treatment, specifically, NSHA, London Health Science Centre (“LHSC”), University Health Network (“UHN”) and McGill University Health Centre (“MUHC”). In addition, the Company has approximately 16 clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is strategically targeting clinical sites throughout Canada and the US (subject to FDA Investigational New Drug (“IND”) approval) that serve large populations or have the demographics to support patient enrollment and treatment. Shawn Shirazi, Ph.D., CEO of Theralase, stated that “I am pleased to announce the addition of NSHA and Dr. Rendon as Principal Investigator. Dr. Rendon is considered an expert in the field with a clinical focus on all areas of uro-oncology.
Right....... just connect the dots........ so Nova Scotia is safe enough to run a Covid 19 trial but we have TLD-1433 1-2 hour operation and a send home situation i.e. minimal hospital stay and you want me to believe that it's all shut down in Nova Scotia.
This for shareholders should be a massive windfall in our favour.. selecting Nova Scotia as a clinical site.. yet we are shi* on...
I think that some explainations are required.. as I also cant see why Shawn Shirazi wouldnt of applied for FTA.. to up our drugs profile from 2020 to 2022 before Breakthrough application...
shrugs....